127 related articles for article (PubMed ID: 36546779)
1. Choroidal Vascular Index in Patients With Attention-Deficit/Hyperactivity Disorder and Methylphenidate.
Kiziltoprak H; Kocabas DO; Aydemir GA; Kalınlı EM; Aydemir E; Oren B
J Pediatr Ophthalmol Strabismus; 2023; 60(6):411-416. PubMed ID: 36546779
[TBL] [Abstract][Full Text] [Related]
2. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
[TBL] [Abstract][Full Text] [Related]
3. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
4. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
[TBL] [Abstract][Full Text] [Related]
5. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
6. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
[TBL] [Abstract][Full Text] [Related]
8. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N
J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523
[TBL] [Abstract][Full Text] [Related]
9. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
10. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
11. Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
Chen VC; Yang YH; Yu Kuo T; Lu ML; Tseng WT; Hou TY; Yeh JY; Lee CT; Chen YL; Lee MJ; Dewey ME; Gossop M
Epidemiol Psychiatr Sci; 2020 Jul; 29():e146. PubMed ID: 32686635
[TBL] [Abstract][Full Text] [Related]
12. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
13. The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder.
Golubchik P; Weizman A
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):429-432. PubMed ID: 28398816
[TBL] [Abstract][Full Text] [Related]
14. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
Deng L; Zhou P; Zhu L; Zhang Y; Yang T; Zhao Q; Chen J; Li T; Cheng Q; Chen L
Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder.
Akkaya S; Ulusoy DM; Doğan H; Arslan ME
Indian J Ophthalmol; 2021 Dec; 69(12):3607-3611. PubMed ID: 34827004
[TBL] [Abstract][Full Text] [Related]
16. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
López FA; Faraone SV; Newcorn JH; Doll HA; Rhoten S; Lewis HB; Khan TF; DeSousa NJ; Sallee FR; Incledon B
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):179-186. PubMed ID: 33797983
[No Abstract] [Full Text] [Related]
17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
18. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
Olfson M; Marcus SC; Zhang HF; Wan GJ
J Manag Care Pharm; 2007 Sep; 13(7):570-7. PubMed ID: 17874863
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy.
Park J; Choi HW; Yum MS; Ko TS; Shon SH; Kim HW
J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):537-546. PubMed ID: 30089215
[TBL] [Abstract][Full Text] [Related]
20. The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder.
Golubchik P; Levy T; Weizman A
Int Clin Psychopharmacol; 2018 Nov; 33(6):330-333. PubMed ID: 29958238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
